Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avastin Pricing Strategy, Expanded Indications Under Review At Genentech

Executive Summary

Genentech may reconsider pricing forAvastin following "phenomenal" clinical trial results evaluating the biologic for first-line non-squamous non-small cell lung cancer and metastatic breast cancer

You may also be interested in...



Roche Sees Avastin As Oncology Backbone, Will Focus On Combinations

Roche and Genentech's plans to establish Avastin (bevacizumab) as the "backbone" standard of care in oncology include a focus on combination use

Roche Sees Avastin As Oncology Backbone, Will Focus On Combinations

Roche and Genentech's plans to establish Avastin (bevacizumab) as the "backbone" standard of care in oncology include a focus on combination use

Genentech Pipeline Puts Firm Ahead Of 2005 Goals, Sailing To “Horizon 2010”

As Genentech enters the final quarter of its multi-year growth plan, the firm is on track to meet or exceed the development and product approval goals set out in its "5x5" plan for the period from 1999 to 2005

Related Content

Topics

UsernamePublicRestriction

Register

PS046070

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel